Critical treatment choices for patients with platinum-refractory urothelial carcinoma

Lancet Oncol. 2020 Jan;21(1):11-13. doi: 10.1016/S1470-2045(19)30661-8. Epub 2019 Nov 18.

Authors

Yair Lotan¹, Xiaosong Meng²

Affiliations

¹ University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: yair.lotan@utsouthwestern.edu.
² University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

PMID: 31753728
DOI: 10.1016/S1470-2045(19)30661-8

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Carcinoma, Transitional Cell*
Docetaxel
Double-Blind Method
Humans
Platinum
Ramucirumab
Urologic Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
Docetaxel
Platinum